Replies to post #298506 on Avid Bioservices Inc (CDMO)

[biopharm]

The binding of Ca2+ translocates PKC to the membrane, where the C1 and C2 domains interact with DAG and Phosphatidylserine, respectively. Phosphatidylserine is the membrane lipid anchor for both cPKCs and nPKCs, although other membrane phospholipids may ultimately link extracellular signals to intracellular events through PKC. This interaction causes the pseudosubstrate domain to dissociate from the catalytic domain, which results in activation of PKC. "

https://www.qiagen.com/kr/shop/genes-and-pathways/pathway-details/?pwid=16

This clearly proves part of the puzzle that those collaborations, most non disclosed .....have been working with Peregrine ( such as Epiontis ...Precision For Medicine ...Immunoscore Jerome Galon worldwide taskforce of partners....John Hopkins....etc etc etc are leveraging PS Targeting Biomarker data for patents ...FDA approvals blood tests...Biomarkers....material event news....etc etc and HOW can CEO Roger Lias sit back and allow it ?

Is he being promised something like CDMO manufacturing customers / orders / $$$...stock options....etc etc all in exchange for turning a blind eye to the PS Targeting IP assets R&D ??

Would a lawsuit be coming if they don't provide answers on what the hell is going on ? At least Steve King you knew where you stood in that he realized the potential and astronomical potential and only had to focus on the sabotage by others in various forms...but here...

We have a CEO that is truly on the verge of being removed from his duties ....due to the lack of integrity and total lack of awareness of how vital the PS Targeting IP assets to Immunotherapy in all phases from diagnostics to treatment of all diseases where flipped PS exists.